- During the latest quarterly update, Amgen Inc AMGN disclosed that it is resuming dosing for pavurutamab (AMG 710) but halted enrollment to a trial for AMG 427. Both were BiTE molecules with extended half-lives.
- It said in February that it’d paused enrollment in the Phase I study for pavurutamab to discuss with the FDA “protocol modifications to optimize safety monitoring and mitigation with the FDA.”
- Pavurutamab is under development for relapsed or refractory multiple myeloma.
- Acute myeloid leukemia candidate, AMG 427, was moved into a phase 1 study in 2018. Last week, Amgen updated the ClinicalTrials.gov listing for the therapy to “active, not recruiting” without explaining the decision to stop enrolling new patients.
- The Company also said it would invest close to $550 million in a drug substance plant in Holly Springs, North Carolina, marking its second drug manufacturing announcement in a little more than a month.
- The North Carolina facility will create more than 350 jobs. Construction will start in 2021 and be completed by 2029.
- Amgen posted a fall in Q2 profit to $464 million from $1.80 billion a year earlier.
- Price Action: AMGN shares are down 6.4% at $228.44 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in